Evidence map›Paper›PMID 32311853›Full record

ArticleAnnals of laboratory medicine2020

Pre-Transplant Angiotensin II Type 1 Receptor Antibodies and Anti-Endothelial Cell Antibodies Predict Graft Function and Allograft Rejection in a Low-Risk Kidney Transplantation Setting.

Shinae Yu, Hee Jae Huh, Kyo Won Lee, Jae Berm Park, Sung-Joo Kim, Wooseong Huh, Hye Ryoun Jang, Ghee Young Kwon, Hyung Hwan Moon, Eun-Suk Kang

Open access · diamondAbstract read
In one paragraph

Article in Annals of laboratory medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Recent Advances on Biomarkers of Early and Late Kidney Graft Dysfunction.International journal of molecular sciences · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Shinae YuDepartment of Laboratory Medicine, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea.ORCID 0000-0002-9527-5853
Hee Jae HuhDepartment of Laboratory Medicine and Genetics, Sungkyunkwan University School of Medicine, Seoul, Korea.ORCID 0000-0001-8999-7561
Kyo Won LeeDepartment of Surgery, Sungkyunkwan University School of Medicine, Seoul, Korea.ORCID 0000-0002-2722-7817
Jae Berm ParkDepartment of Surgery, Sungkyunkwan University School of Medicine, Seoul, Korea.ORCID 0000-0001-9117-2278
Sung-Joo KimDepartment of Surgery, Sungkyunkwan University School of Medicine, Seoul, Korea.ORCID 0000-0001-9251-1673
Wooseong HuhOrgan Transplantation Center, Sungkyunkwan University School of Medicine, Seoul, Korea.ORCID 0000-0001-8174-5028
Hye Ryoun JangOrgan Transplantation Center, Sungkyunkwan University School of Medicine, Seoul, Korea.ORCID 0000-0001-9856-6341
Ghee Young KwonDepartment of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.ORCID 0000-0002-5551-4178
Hyung Hwan MoonDepartment of Surgery Kosin University Gospel Hospital, Medical College of Kosin University, Busan, Korea.ORCID 0000-0002-4212-4568
Eun-Suk KangDepartment of Laboratory Medicine and Genetics, Sungkyunkwan University School of Medicine, Seoul, Korea.ORCID 0000-0001-6386-6520
Samsung Medical Center · KRInje University Haeundae Paik Hospital · KRKosin University Gospel Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNon-HLA antibodies, anti-angiotensin II type 1 receptor antibodies (anti-AT1R) and anti-endothelial cell antibodies (AECA), are known to play a role in allograft rejection. We evaluated the role of both antibodies in predicting post-transplant outcomes in low-risk living donor kidney transplantation (LDKT) recipients.

methodsIn 94 consecutive LDKT recipients who were ABO compatible and negative for pre-transplant HLA donor-specific antibodies, we determined the levels of anti-AT1Rs using an enzyme-linked immunosorbent assay and the presence of AECAs using a flow cytometric endothelial cell crossmatch (ECXM) assay with pre-transplant sera. Hazard ratio (HR) was calculated to predict post-transplant outcomes.

resultsPre-transplant anti-AT1Rs (≥11.5 U/mL) and AECAs were observed in 36 (38.3%) and 22 recipients (23.4%), respectively; 11 recipients had both. Pre-transplant anti-AT1Rs were a significant risk factor for the development of acute rejection (AR) (HR 2.09; P=0.018), while a positive AECA status was associated with AR or microvascular inflammation only (HR 2.47; P=0.004) throughout the follow-up period. In particular, AECA (+) recipients with ≥11.5 U/mL anti-AT1Rs exhibited a significant effect on creatinine and estimated glomerular filtration rate (P<0.001; P=0.028), although the risk of AR was not significant.

conclusionsPre-transplant anti-AT1Rs and AECAs have independent negative effects on post-transplant outcomes in low-risk LDKT recipients. Assessment of both antibodies would be helpful in stratifying the pre-transplant immunological risk, even in low-risk LDKT recipients.

Indexed as

Kidney TransplantationAdultAntibodiesAutoantibodiesCreatinineFemaleGlomerular Filtration RateGraft RejectionHumansKaplan-Meier EstimateKidneyMaleMiddle AgedProportional Hazards ModelsReceptor, Angiotensin, Type 1Risk FactorsAntibodiesanti-endothelial cell antibodyAutoantibodiesCreatinineReceptor, Angiotensin, Type 1Anti-angiotensin II type 1 receptor antibodiesAnti-endothelial cell antibodiesEndothelial cell crossmatchKidney transplantationLow-riskNon-HLA antibodiesOutcome

Identifiers

PMID32311853
PMCPMC7169631
OpenAlexW3017073570

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.